Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.

Chemotherapy-induced nausea and vomiting (CINV) continues to be one of the most distressing side effects of chemotherapy in breast cancer patients, which can result in poor compliance to therapy that may, in turn, affect overall survival. The extent of CINV is dependent on the emetogenic potential of the individual cytotoxic agents or regimens employed as well as certain patient factors. Advances in our understanding in the pathophysiology of CINV and the identification of risk factors have enabled the utilization of appropriate antiemetic regimens to improve the control of CINV. Most of the chemotherapy regimens used in this patient population are considered to be moderately emetogenic; 60%-90% of chemotherapeutic regimens used in breast cancer patients cause nausea and vomiting, amongst which regimens doxorubicin-cyclophosphamide (AC) combination is commonly regarded as of relatively higher emetogenicity. Currently, corticosteroids, 5-hydroxytryptamine 3 (5-HT3) receptor antagonists, and neurokinin 1 (NK-1) receptor antagonists are the three classes of antiemetic agents with the highest therapeutic index, which have been supported by data from large-scale randomized clinical trials. Treatment guidelines enable physicians to integrate the latest research data into their clinical practices. This review focuses on the three classes of antiemetic therapy options for CINV in breast cancer patients, as well as their safety and tolerability profiles. Recommendations from major guidelines/consensus including from the Multinational Association for Supportive Care in Cancer/European Society of Medical Oncology (MASCC/ESMO), the American Society of Clinical Oncology (ASCO), and the US National Comprehensive Cancer Network (NCCN), are also discussed. With the correct use of antiemetic regimens, chemotherapy-induced vomiting could be prevented in the majority of patients. However, chemotherapy-induced nausea remains an important symptom and a challenge for physicians to manage.

[1]  H. Muss,et al.  Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy , 2005, Cancer.

[2]  R. Navari.  Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. , 2006, Future oncology.

[3]  Doherty Km.  Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. , 1999 .

[4]  M. Kris,et al.  Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy , 2005, Supportive Care in Cancer.

[5]  F. Roila,et al.  The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials , 2005 .

[6]  D. Carney,et al.  Chemotherapy induced nausea and vomiting. , 1994, Irish medical journal.

[7]  C. Butler,et al.  Evaluation of ondansetron prescribing in US academic medical centers. , 1994, Archives of internal medicine.

[8]  Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. , 1995, The New England journal of medicine.

[9]  R. Gralla,et al.  Antiemetic efficacy of the neurokinin‐1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high‐dose cisplatin , 2005, Cancer.

[10]  J. Koeller,et al.  Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine3 Receptor Antagonists , 2003, The Annals of pharmacotherapy.

[11]  V. Cocquyt,et al.  Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients , 2005, Cancer Chemotherapy and Pharmacology.

[12]  M. Kris,et al.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Navari.  Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting , 2007, Expert opinion on investigational drugs.

[14]  J. Koeller,et al.  Acute emesis: moderately emetogenic chemotherapy , 2005, Supportive Care in Cancer.

[15]  T. Bradstreet,et al.  Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 Activity , 2004, Journal of clinical pharmacology.

[16]  J. Hajdenberg,et al.  Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist , 2003, Cancer.

[17]  M. Aapro,et al.  Aprepitant: drug-drug interactions in perspective. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Keunchil Park,et al.  Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  P. Rothenberg,et al.  Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin , 2005, European Journal of Clinical Pharmacology.

[20]  H. Eichler,et al.  Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Tonini,et al.  Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? , 2003, Supportive Care in Cancer.

[22]  Z. Aziz,et al.  Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Aapro,et al.  Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy , 2010, Supportive Care in Cancer.

[24]  C. Bountra,et al.  Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. , 1993, European journal of pharmacology.

[25]  C. Perry,et al.  Aprepitant , 2012, Drugs.

[26]  C. Lines,et al.  Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone , 2003, Clinical pharmacology and therapeutics.

[27]  F. Roila,et al.  The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. , 2005, European journal of cancer.

[28]  M. Aapro,et al.  Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  R. Kaiser.  Antiemetic guidelines: are they being used? , 2005, The Lancet. Oncology.

[30]  R. Navari.  Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist , 2009, Expert opinion on drug metabolism & toxicology.

[31]  F. Roila,et al.  The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Aapro,et al.  Comparative activity of antiemetic drugs. , 2007, Critical reviews in oncology/hematology.

[33]  Drug Utilization Review Team in Oncology.  Antiemetic prescription in Italian breast cancer patients submitted to adjuvant chemotherapy , 2003, Supportive Care in Cancer.

[34]  O. Clark,et al.  Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis , 2011, Supportive Care in Cancer.

[35]  K. L. Lenz,et al.  Aprepitant: A Novel Antiemetic for Chemotherapy-Induced Nausea and Vomiting , 2005, The Annals of pharmacotherapy.

[36]  A. Favero,et al.  Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  K. Horgan,et al.  Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting , 2003, Cancer.

[38]  F. Shepherd,et al.  Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy , 1995, Supportive Care in Cancer.

[39]  M. Decramer,et al.  Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869 , 2002, Cancer.

[40]  Lisa K Lohr,et al.  Chemotherapy-Induced Nausea and Vomiting , 2008, Cancer journal.

[41]  M. Decramer,et al.  Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. , 2001, European journal of cancer.

[42]  D. Amadori,et al.  Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  P. Rameshwar,et al.  Neurokinin receptors as potential targets in breast cancer treatment. , 2008, Current drug discovery technologies.

[44]  R. Labianca,et al.  Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  D. Osoba,et al.  Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  S. Rodenhuis,et al.  Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism , 2005, Cancer Chemotherapy and Pharmacology.

[47]  R. Gralla,et al.  Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Kris,et al.  Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  L. Cavanna,et al.  Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial , 2010, Supportive Care in Cancer.

[50]  C. Kitagawa,et al.  Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. , 2009, The Lancet. Oncology.

[51]  D. Warr,et al.  Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy , 2011, Supportive Care in Cancer.

[52]  T. Weisberg,et al.  Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy , 2009, Supportive Care in Cancer.

[53]  J. Carmichael,et al.  Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. , 1994, British Journal of Cancer.

[54]  K. Doherty.  Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. , 1999, Clinical journal of oncology nursing.

[55]  J. Hardwick,et al.  Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. Navari,et al.  Emerging drugs for chemotherapy-induced emesis , 2006, Expert opinion on emerging drugs.

[57]  W. Lau,et al.  A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy , 2009, Breast Cancer Research and Treatment.